
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

VolitionRx Limited

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

928661206

(CUSIP Number)

Jason A. Ozone
Lagoda Investment Management, L.P., 3 Columbus Circle, Floor 15
New York, NY, 10019
(212) 309-7660

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/15/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP 928661206
Number(s):

1	Name of reporting person Lagoda Investment Management, L.P.
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only

4	Source of funds (See Instructions) WC, OO	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 1,650,505.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 1,650,505.00
11	Aggregate amount beneficially owned by each reporting person 1,650,505.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 5.9 %	
14	Type of Reporting Person (See Instructions) IA	

Comment for Type of Reporting Person:
See Item 2 of the Schedule 13D for additional information.

SCHEDULE 13D

CUSIP 928661206
Number(s):

1	Name of reporting person Lagoda Investment Management, LLC
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only
4	Source of funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 1,650,505.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 1,650,505.00
11	Aggregate amount beneficially owned by each reporting person 1,650,505.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 5.9 %	
14	Type of Reporting Person (See Instructions) HC	

Comment for Type of Reporting Person:
See Item 2 of the Schedule 13D for additional information.

SCHEDULE 13D

CUSIP Number(s):	928661206
------------------	-----------

1	Name of reporting person Fatima Dickey
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☐ (b)
3	SEC use only
4	Source of funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 1,650,505.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 1,650,505.00
11	Aggregate amount beneficially owned by each reporting person 1,650,505.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 5.9 %	
14	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person:

See Item 2 of the Schedule 13D for additional information.

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, par value \$0.001 per share

(b) Name of Issuer:

VolitionRx Limited

(c) Address of Issuer's Principal Executive Offices:

1489 West Warm Springs Road, Suite 110, Henderson, NEVADA , 89014.

Item 1 Comment:

This Amendment No. 1 to Schedule 13D (this "Amendment") amends and supplements the Schedule 13D filed by the Reporting Persons with the Securities and Exchange Commission on September 4, 2026 (the "Schedule 13D"). Capitalized terms used but not defined in this Amendment have the meanings given to them in the Schedule 13D. Except as specifically amended by this Amendment, the Schedule 13D remains unchanged.

Item 2. Identity and Background

(a) Not amended.

Item 3. Source and Amount of Funds or Other Consideration

Not amended.

Item 4. Purpose of Transaction

Not amended.

Item 5. Interest in Securities of the Issuer

(a) As of the date of this Amendment, each of the Reporting Persons may be deemed to beneficially own, in the aggregate, 1,650,505 shares of Common Stock, consisting of (i) 1,479,450 shares of Common Stock held in the Accounts and (ii) warrants exercisable for an aggregate of 171,055 shares of Common Stock held in the Accounts. The aggregate holdings reported herein represent approximately 5.9% of the outstanding Common Stock, calculated in accordance with Rule 13d-3 of the Securities Exchange Act based on (x) 27,903,326 shares of Common Stock outstanding as of September 14, 2026, as reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 15, 2026, plus (y) 171,055 shares of Common Stock issuable upon exercise of warrants deemed beneficially owned by the Reporting Persons.

(b) See rows (7) through (10) of the cover pages to this Amendment, which are incorporated herein by reference.

- (c) On September 16, 2026, the Investment Manager sold 1,500 shares of Common Stock in an open-market transaction at a price of \$0.2855 per share.
Except as set forth above, the Reporting Persons have not effected any other transactions in the Common Stock since September 4, 2026.
- (d) Not amended.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Not amended.

Item 7. Material to be Filed as Exhibits.

Not amended.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lagoda Investment Management, L.P.

Signature: /s/ Jason A. Ozone
Name/Title: Jason A. Ozone, Chief Financial Officer & Chief Compliance Officer
Date: 09/16/2026

Lagoda Investment Management, LLC

Signature: /s/ Fatima Dickey
Name/Title: Fatima Dickey, Sole Member
Date: 09/16/2026

Fatima Dickey

Signature: /s/ Fatima Dickey
Name/Title: Fatima Dickey
Date: 09/16/2026

Comments accompanying signature:
Not applicable.